SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp

NEXT STORY
Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19
PREV STORY
Preclinical Data Supporting Therapeutic Potential of Surface Oncology’s Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Eton Pharmaceuticals Reports Record Revenue and Earnings

author_avatar
NASDAQ Market News

Celsion Corporation Announces Stock Consolidation

LAWRENCEVILLE, N.J., May 26, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug ...

author_avatar
NASDAQ Market News

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders

author_avatar
NASDAQ Market News